LU92903I2 - Gardasil-9/nom du produit:protéine hpv 52 l1 - Google Patents

Gardasil-9/nom du produit:protéine hpv 52 l1 Download PDF

Info

Publication number
LU92903I2
LU92903I2 LU92903C LU92903C LU92903I2 LU 92903 I2 LU92903 I2 LU 92903I2 LU 92903 C LU92903 C LU 92903C LU 92903 C LU92903 C LU 92903C LU 92903 I2 LU92903 I2 LU 92903I2
Authority
LU
Luxembourg
Prior art keywords
gardasil
product name
protein hpv
hpv
protein
Prior art date
Application number
LU92903C
Other languages
English (en)
French (fr)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LU92903I2 publication Critical patent/LU92903I2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92903C 2004-03-24 2015-12-08 Gardasil-9/nom du produit:protéine hpv 52 l1 LU92903I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55592604P 2004-03-24 2004-03-24
EP05725933A EP1730175B1 (en) 2004-03-24 2005-03-18 Optimized expression of hpv 52 l1 in yeast
PCT/US2005/009199 WO2005097821A1 (en) 2004-03-24 2005-03-18 Optimized expression of hpv 52 l1 in yeast

Publications (1)

Publication Number Publication Date
LU92903I2 true LU92903I2 (fr) 2016-03-08

Family

ID=34964085

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92903C LU92903I2 (fr) 2004-03-24 2015-12-08 Gardasil-9/nom du produit:protéine hpv 52 l1

Country Status (31)

Country Link
US (2) US7700103B2 (hu)
EP (1) EP1730175B1 (hu)
JP (1) JP4833962B2 (hu)
KR (1) KR101203403B1 (hu)
CN (1) CN1934131B (hu)
AR (1) AR048191A1 (hu)
AT (1) ATE466022T1 (hu)
AU (1) AU2005230907C1 (hu)
BE (1) BE2015C066I2 (hu)
BR (1) BRPI0509079B8 (hu)
CA (1) CA2560487C (hu)
CY (2) CY1110349T1 (hu)
DE (1) DE602005020913D1 (hu)
DK (1) DK1730175T3 (hu)
ES (1) ES2343255T3 (hu)
FR (1) FR15C0085I2 (hu)
HU (1) HUS1500062I1 (hu)
IL (1) IL178140A (hu)
LT (2) LTPA2015050I1 (hu)
LU (1) LU92903I2 (hu)
MY (1) MY148656A (hu)
NL (1) NL300777I1 (hu)
NO (2) NO338055B1 (hu)
NZ (1) NZ549898A (hu)
PL (1) PL1730175T3 (hu)
PT (1) PT1730175E (hu)
RU (1) RU2373219C2 (hu)
SI (1) SI1730175T1 (hu)
TW (1) TWI349036B (hu)
WO (1) WO2005097821A1 (hu)
ZA (1) ZA200607575B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN1869215B (zh) * 2006-05-19 2012-07-04 长春百克生物科技股份公司 一种制备人乳头瘤病毒的病毒样颗粒的方法
EP2129394B1 (en) 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
CN101440371B (zh) * 2007-11-23 2012-09-05 上海泽润生物科技有限公司 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
KR20180082633A (ko) * 2010-05-14 2018-07-18 박스알타 인코퍼레이티드 Ospa 키메라 및 백신에서 그의 용도
AU2011258501B2 (en) 2010-05-25 2016-07-07 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
DK2589604T3 (en) * 2010-07-02 2017-01-16 Univ Xiamen TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 52
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
CN103562392B (zh) 2010-12-03 2016-07-20 Ms技术有限责任公司 植物细胞中草甘膦抗性编码核酸分子的优化表达
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106701796B (zh) * 2015-08-12 2021-11-16 北京康乐卫士生物技术股份有限公司 52型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
WO2021163002A1 (en) 2020-02-14 2021-08-19 Merck Sharp & Dohme Corp. Hpv vaccine
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
US20230048144A1 (en) 2021-08-06 2023-02-16 Merck Sharp & Dohme Llc Hpv vaccine
WO2023023152A1 (en) 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Thermostable lipid nanoparticle and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339729C (en) * 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
ES2274566T3 (es) 1997-02-07 2007-05-16 MERCK & CO., INC. Genes gag del vih sinteticos.
WO1999002694A1 (en) 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
JP4563582B2 (ja) 1998-08-14 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション ヒトパピローマウイルスのウイルス様粒子を使用するタンパク質送達系
CN1354787A (zh) * 1998-08-14 2002-06-19 麦克公司 纯化人乳头瘤病毒样颗粒的方法
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
CA2381991A1 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic human papillomavirus genes
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
CN1262665C (zh) 2000-07-21 2006-07-05 葛兰素集团有限公司 经过密码子最优化的乳头状瘤病毒序列
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
MXPA05010285A (es) 2003-03-24 2005-11-17 Merck & Co Inc Expresion optimizada de hpv 31 l1 en levadura.
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast

Also Published As

Publication number Publication date
PL1730175T3 (pl) 2010-09-30
RU2373219C2 (ru) 2009-11-20
BRPI0509079B8 (pt) 2021-07-06
FR15C0085I2 (fr) 2016-11-25
ZA200607575B (en) 2008-08-27
BRPI0509079B1 (pt) 2020-05-19
US7700103B2 (en) 2010-04-20
CA2560487A1 (en) 2005-10-20
US20100035818A1 (en) 2010-02-11
IL178140A0 (en) 2006-12-31
AU2005230907B2 (en) 2011-05-19
CA2560487C (en) 2013-01-29
US20080226660A1 (en) 2008-09-18
LTC1730175I2 (lt) 2017-05-10
PT1730175E (pt) 2010-06-25
ES2343255T3 (es) 2010-07-27
DK1730175T3 (da) 2010-08-23
JP4833962B2 (ja) 2011-12-07
SI1730175T1 (sl) 2010-08-31
CY2015052I2 (el) 2016-06-22
BRPI0509079A (pt) 2007-08-21
JP2007530040A (ja) 2007-11-01
AU2005230907A1 (en) 2005-10-20
CY2015052I1 (el) 2016-06-22
FR15C0085I1 (hu) 2016-08-01
TW200602490A (en) 2006-01-16
LTPA2015050I1 (lt) 2016-01-11
CN1934131B (zh) 2010-12-29
DE602005020913D1 (de) 2010-06-10
MY148656A (en) 2013-05-15
CY1110349T1 (el) 2015-04-29
US7744892B2 (en) 2010-06-29
AU2005230907C1 (en) 2016-07-28
NO20064815L (no) 2006-10-23
IL178140A (en) 2010-11-30
KR20060134120A (ko) 2006-12-27
EP1730175A1 (en) 2006-12-13
ATE466022T1 (de) 2010-05-15
WO2005097821A1 (en) 2005-10-20
NZ549898A (en) 2009-06-26
AR048191A1 (es) 2006-04-05
TWI349036B (en) 2011-09-21
NO338055B1 (no) 2016-07-25
EP1730175B1 (en) 2010-04-28
CN1934131A (zh) 2007-03-21
NL300777I2 (hu) 2015-12-29
NO2017005I1 (no) 2017-01-20
NL300777I1 (hu) 2015-12-29
BE2015C066I2 (hu) 2024-08-08
RU2006137363A (ru) 2008-04-27
KR101203403B1 (ko) 2012-11-21
HUS1500062I1 (hu) 2017-07-28

Similar Documents

Publication Publication Date Title
LU92903I2 (fr) Gardasil-9/nom du produit:protéine hpv 52 l1
LU92902I2 (fr) Gardasil-9/nom du produit: protéine hpv 45 l1
LU92901I2 (fr) Gardasil-9/ nom du produit: protéine hpv58l1
DE602004012052D1 (de) Akustisch gekoppelter Produktaufkleber
DE602004029184D1 (de) Einwegscheuerprodukt
FR2877842B1 (fr) Produit aerosol anti-transpirant
FR2838048B1 (fr) Produit dentaire reticulable/dereticulable
LU92900I2 (fr) Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31
DE502005003152D1 (de) Produktbehälter
FIU20070081U0 (fi) Saniteettituote
SE0301552L (sv) New product
SE0300002L (sv) Ny produkt
FR2873312B1 (fr) Produit pour biotraitement environnemental
DK1691751T3 (da) Hygiejneprodukt
FR2892012B1 (fr) Procede d'epilation
ATE374761T1 (de) Syntheseverfahren und benzoxathiepinzwischenprodukte
FR2850973B1 (fr) Produit bi-composant
FR2856994B1 (fr) Ensemble de distribution de produit
FR2865432B1 (fr) Materiau d'operculage ludique
FR2871690B3 (fr) Produit cosmetique antirides
ITBG20040037A1 (it) Prodotto dolciario
ITMO20050281A1 (it) Prodotto dolciario
UA10221S (uk) Гігієнічний виріб
UA8093S (uk) Етикетка для молочних виробів
FR2889913B1 (fr) Ensemble d'allumettes